⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RMD News
ResMed Inc.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
globenewswire.com
ERAS
RMD
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
prnewswire.com
PFE
ABBV
RMD
GSK
AZN
BNTX
INCY
IOVA
RGEN
MRK
LLY
IBIO
GILD
AMGN
JNJ
NVS
RIGL
BIIB
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
globenewswire.com
RMD
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines – ERAS
globenewswire.com
ERAS
RMD
Publication relating to transparency notifications
globenewswire.com
NYXH
RMD
At a Turning Point for RAS-directed Therapies, Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
prnewswire.com
RMD
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
ERAS
RMD
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
globenewswire.com
ERAS
RMD
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
globenewswire.com
RMD
Pomerantz LLP Advises Shareholders of Class Action Against Erasca, Inc. – ERAS
accessnewswire.com
ERAS
RMD